The 145th Annual Meeting of the Pharmaceutical Society of Japan (Fukuoka)

Organizer: Takeshi Fuchigami (Grad. Sch. Pharm., Kanazawa Univ.), Hiroyuki Suzuki (Grad. Sch. Pharm., Chiba Univ.)

At-211 is one of the few alpha-emitting radionuclides for which a production method has been established in Japan, possessing a suitable half-life of 7.2 hours and exhibiting a potent anti-cancer effect. For this reason, several production facilities have been established in Japan in recent years, and research has progressed from basic science to clinical application, raising expectations for the next generation of cancer treatment.
However, long-term retention of At-211-labeled radioligands in non-target tissues or their degradation by metabolism may reduce therapeutic efficacy and cause side effects. Therefore, research aimed at improving the biodistribution and stability of At-211-labeled radioligands has been intensively conducted. In addition, elucidating the molecular mechanisms of therapeutic efficacy and side effects is also an important issue, and various studies are being conducted. In this trend, clinical trials of At-211-labeled radiopharmaceuticals, which have shown excellent anti-cancer activity, have been initiated, and further progress is expected.
In this symposium, five speakers will present the current status of alpha-ray emitting radionuclide production, the latest research on At-211-labeled drug development, research on therapeutic mechanisms, and ongoing promising clinical trials. The purpose of this symposium is to promote a broad understanding of this field and its future development.